You are here

FDA Advisors Recommend Approval of Hypertension Drug Riociguat (Adempas), But at Lower Doses

Drug treats two types of pulmonary hypertension (August 2)

According to Reuters, the FDA’s Cardiovascular and Renal Drugs Advisory Committee has recommended that the agency approve riociguat (Adempas), an experimental drug to treat two types of pulmonary hypertension, but at lower doses than those proposed by the drug’s developer (Bayer).

The reviewers’ report was issued ahead of their formal meeting on the drug, scheduled for August 6.

Riociguat was developed to improve exercise ability in patients with chronic thromboembolic pulmonary hypertension (CTEPH) or pulmonary arterial hypertension (PAH).

The advisory committee had concerns about the drug’s potential to cause bleeding and hypotension, and its effect on renal function.

Riociguat is the first-in-class of a new group of compounds, soluble guanylate cyclase (sGC) stimulators. sGC is a key enzyme in the cardiopulmonary system and the receptor for nitric oxide (NO). Both CTEPH and PAH are associated with endothelial dysfunction, leading to an imbalance in circulating levels of endogenous vasodilators and vasoconstrictors.

Sources: Reuters; August 2, 2013; and Bayer HealthCare; August 2013.

Recent Headlines

Despite older, sicker patients, mortality rate fell by a third in 10 years
Study finds fewer than half of trials followed the law
WHO to meet tomorrow to decide on international public heath emergency declaration
Study of posted prices finds wild variations and missing data
Potential contamination could lead to supply chain disruptions
Declining lung cancer mortality helped fuel the progress
Kinase inhibitor targets tumors with a PDGFRA exon 18 mutation
Delayed surgery reduces benefits; premature surgery raises risks
Mortality nearly doubled when patients stopped using their drugs